ImaginAb Announces New Supply Agreement to Supply Genmab A/S with its investigational CD8 ImmunoPET agent

LOS ANGELES, May 5, 2022 /PRNewswire/ -- ImaginAb, Inc., a market leading global biotechnology company focused on developing next generation ImmunoPET imaging agents and therapeutic radiopharmaceuticals (RPT), is pleased to announce it has signed a new multi-year, non-exclusive supply...

Click to view original post